

Section 3 Title: Profiling Wet AMD

Author: Ursula Oetiker

References

1. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. *Eye* 2008; 22(7):905-911.
2. The Royal College of Ophthalmologists. Commissioning contemporary AMD services: a guide for commissioners and clinicians - version 3. 2007. <http://www.rcophth.ac.uk/docs/publications/published-guidelines/CommissionContempAMDServicesV3Final.pdf>. Accessed 12-01-2009.
3. Ferris FL, III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. *Arch Ophthalmol* 1984; 102(11):1640-1642.
4. NICE. Ranibizumab and pegaptanib for age-related macular degeneration: final appraisal determination. <http://www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf>. Accessed 4-1-2009.
5. AMD Alliance website. <http://www.amdalliance.org/information/basicfacts/typesofamd.php> . Accessed 1-12-2008.
6. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. *Ophthalmology* 2004; 111(5):931-939.
7. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. *J Am Board Fam Pract* 2002; 15(2):142-152
8. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. *N Engl J Med* 2008; 358(24):2606-2617.
9. Kanski JJ. Acquired macular disorders. *Clinical Ophthalmology: a systematic approach*. Elsevier Ltd, 2003: 389-437.
10. Sunness JS, Rubin GS, Applegate CA, Bressler NM, Marsh MJ, Hawkins BS et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. *Ophthalmology* 1997; 104(10):1677-1691.

11. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Mones J, Xu X et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. *Arch Ophthalmol* 2007; 125(9):1249-1254.
12. Scott IU, Smiddy WE, Schiffman J, Feuer WJ, Pappas CJ. Quality of life of low-vision patients and the impact of low-vision services. *Am J Ophthalmol* 1999; 128(1):54-62.
13. Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. *Br J Ophthalmol* 2003; 87(1):8-12.
14. Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J et al. The burden of age-related macular degeneration: a value-based medicine analysis. *Trans Am Ophthalmol Soc* 2005; 103:173-184.
15. Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. *Br J Ophthalmol* 2007; 91(10):1303-1307.
16. Wen F, Wu DZ, Wu L, Yi Y, Feng G, Zheng J. The natural history of dry type of age-related macular degeneration. *Yan Ke Xue Bao* 1993; 9(1):31-33.
17. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. *Ophthalmology* 2008; 115(1):116-126.
18. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol* 2001; 119(10):1417-1436.
19. Anon. TA68: Guidance on the use of photodynamic therapy for age-related macular degeneration. 2003. http://www.nice.org.uk/nicemedia/pdf/68_PDTGuidance.pdf. Accessed 12-01-2009.
20. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006; 355(14):1419-1431.

21. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004; 351(27):2805-2816.
22. Pieramici DJ, Bressler SB. Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye. *Curr Opin Ophthalmol* 1998; 9(3):38-46.